All patients
stage IIIa stage IIIb stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - (neo)adjuvant (NA), ipilimumab alone vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 0.87 [0.66; 1.14]
0.87 [0.66 ; 1.14 ] CheckMate 238, 2017 1 0% 906 NA not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
0.65 [0.51 ; 0.83 ] CheckMate 238, 2017 1 0% 906 NA not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
0.49 [0.20 ; 1.23 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
0.28 [0.21 ; 0.37 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
0.15 [0.10 ; 0.21 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
0.11 [0.07 ; 0.18 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 0.25 [0.15; 0.43]
0.25 [0.15 ; 0.43 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.20 [0.14; 0.27]
0.20 [0.14 ; 0.27 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 0.12 [0.08; 0.17]
0.12 [0.08 ; 0.17 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.09 [0.05; 0.15]
0.09 [0.05 ; 0.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.02; 14.96]
0.50 [0.02 ; 14.96 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.03; 2.24]
0.25 [0.03 ; 2.24 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.15 [0.07; 0.34]
0.15 [0.07 ; 0.34 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
0.10 [0.05 ; 0.20 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.14 [0.02; 1.15]
0.14 [0.02 ; 1.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
0.15 [0.07 ; 0.32 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 1.00 [0.06; 16.07]
1.00 [0.06 ; 16.07 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.04; 0.81]
0.18 [0.04 ; 0.81 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.02; 0.44]
0.10 [0.02 ; 0.44 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.07; 0.48]
0.18 [0.07 ; 0.48 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.05 [0.00; 0.95]
0.05 [0.00 ; 0.95 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.01; 1.82]
0.10 [0.01 ; 1.82 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.35 [0.13; 0.98]
0.35 [0.13 ; 0.98 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
0.18 [0.07 ; 0.46 ] CheckMate 238, 2017 1 0% 905 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 06:15 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 284,70,235
- treatments: 329,558